Novo Nordisk China Pharmaceuticals Co. Ltd.

In the fierce competition of the global weight loss market, semaglutide has stood out for its impressive weight loss effects, attracting the attention of many obese patients and those seeking to improve their physique. Notably, the drug has rapidly become a star product in the weight loss field, hailed as the "champion" of weight loss, thanks to the positive endorsement of prominent figures like Elon Musk. However, a recent study published in the "International Journal of Impotence Research," a sub-journal of "Nature," has raised questions about this much-touted drug. The study found that non-diabetic men taking semaglutide had a 4.5-fold increased risk of developing erectile dysfunction (ED), a finding that has undoubtedly cast a shadow over this "champion" drug. In response to these research findings, Novo Nordisk China stated that the association between semaglutide and male erectile dysfunction is not mentioned in the Wegovy prescribing information. Novo Nordisk also emphasized that it did not participate in this study and believes that the study lacks sufficient information on drug dosage and treatment duration, making it difficult to confirm whether the conclusions apply to long-term weight management. Furthermore, Novo Nordisk stated that its drug has been extensively validated, with over 11 million patients' worth of usage experience, and the company is always committed to ensuring patient safety. The company will continue to closely monitor adverse reaction reports to ensure the safety of patients' medication use. Concurrently, the R&D competition in the domestic GLP-1 field is also heating up. Whether it's single-target, dual-target, or triple-target drugs, or oral small molecules and biosimilars, various pharmaceutical companies are actively investing in the development of new GLP-1 drugs. Statistics show that more than 100 new GLP-1 drugs have entered the clinical stage, fully demonstrating the domestic research and development capabilities and innovative vitality in this field. It is worth mentioning that Ozempic (semaglutide), Novo Nordisk's flagship therapy, presented the latest results of its FLOW clinical phase 3 trial at the European Renal Association (ERA) conference. The trial results showed that Ozempic performed excellently on the primary and all secondary endpoints, reducing the risk of major cardiovascular events by 18% and the risk of death from any cause by 20% in patients with chronic kidney disease (CKD) and type 2 diabetes. This important achievement provides strong support for the broader application of Ozempic in a wider patient population. Novo Nordisk plans to submit regulatory applications for Ozempic label expansion to the US and EU in 2024, further expanding its market reach. In summary, while semaglutide has demonstrated outstanding weight loss effects as a highly anticipated weight loss drug, whether it has side effects such as ED requires further research and verification. At the same time, the R&D enthusiasm in the domestic GLP-1 field is high, and more new treatment options are expected to emerge in the future, providing patients with more diverse and personalized treatment options.